0001636050-21-000099.txt : 20211209 0001636050-21-000099.hdr.sgml : 20211209 20211209183132 ACCESSION NUMBER: 0001636050-21-000099 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211208 FILED AS OF DATE: 20211209 DATE AS OF CHANGE: 20211209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nassif David W. CENTRAL INDEX KEY: 0001636975 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 211483152 MAIL ADDRESS: STREET 1: C/O STEADYMED THERAPEUTICS, INC. STREET 2: 2410 CAMINO RAMON CITY: SAN RAMON STATE: CA ZIP: 94583 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sio Gene Therapies Inc. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853863315 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 877-746-4891 MAIL ADDRESS: STREET 1: 130 WEST 42ND STREET STREET 2: 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Gene Therapies Ltd. DATE OF NAME CHANGE: 20190516 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 4 1 wf-form4_163909267819349.xml FORM 4 X0306 4 2021-12-08 0 0001636050 Sio Gene Therapies Inc. SIOX 0001636975 Nassif David W. C/O SIO GENE THERAPIES INC. 130 WEST 42ND STREET, 26TH FLOOR NEW YORK NY 10036 0 1 0 0 Chief Financial Officer Common Stock 2021-12-08 4 A 0 17534 0 A 51538 D Common Stock 2021-12-08 4 F 0 6294 1.42 D 45244 D Restricted Stock Units 2021-12-08 4 D 0 17534 0 D Common Stock 17534.0 35066 D The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted. 50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. David Nassif 2021-12-09